Abstract

A STUDY ON PHARMACOECONOMIC EVALUATION AND OUTCOME MEASURES OF ANTIDIABETIC AGENTS

Hisana Moosa*, Sepideh Habibollahi Najafabadi, Muhammad Hashir V. K., Dr. Umesh M. and Dr. Mahendra Kumar Betur Jayappa

ABSTRACT

Background: Diabetes mellitus is a common condition which needs hospitalisation in many cases. It can be treated either by Insulin or OHA (Oral Hypoglycemic Agents).Cost of treatment may vary according to the selection of medications. Clinicians awareness on anti diabetic agents prescription will lead to better patient outcomes at lower cost. Objectives: To evaluate oral hypoglycemic agents vs insulin analogues based on pharmacoeconomic study and its outcome measures. Methodology: The study was performed as a prospective method to analyse the pharmacoeconomics of drugs prescribed widely in management of diabetes mellitus over a period of 6 months. All necessary data were collected in well-designed data collection form, from the patient's treatment chart and assessed. Result: A total of 130 patients' treatment charts were reviewed. It was identified that antidiabetic drugs were prescribed for between the age group of 25 to 899 years of age.85 were male and 45 were female. Among 130 patients 87 patients were taking insulin treatment, In this 87 patients, 66 (75.8%) patients were treated in (SC)subcutaneous route of administration and 21(24.1%) patients through (IV) intravenous route of administration. The average cost spent by a patient for treatment with Insulin was found to be 155.2987059 rupees. The average cost of treatment by OHA was found to be 78.14656944 rupees. Average cost spent for Antihypertensive drugs was found to be 41.84295652 rupees. Average cost for treatment with antiemetic was found to be 128.8105357 rupees. The average cost of treatment with Antacid was found to be 257.5591139 rupees. Feedbacks from the PG doctors were obtained. Conclusion: Pharmacoeconomic evaluation and outcome measures of antidiabetic agents is the need of the hour topic. Use of anti diabetic agents should be individualised with respect to each patient’s diagnosis, signs and symptoms, and other treatments to avoid irrationality, promote the rational use of drugs and avoid errors.

Keywords: Diabetes mellitus, Anti diabetic, Pharmacoeconomics.